tiprankstipranks
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
PremiumPress ReleasesAlterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
4d ago
Alterity’s ATH434 Shows Hope in MSA Trial
PremiumCompany Announcements
Alterity’s ATH434 Shows Hope in MSA Trial
4d ago
Alterity Therapeutics Halts Trading for Clinical Update
PremiumCompany Announcements
Alterity Therapeutics Halts Trading for Clinical Update
6d ago
Alterity announces DMC recommends to continue Phase 2 study of ATH434-201
PremiumThe FlyAlterity announces DMC recommends to continue Phase 2 study of ATH434-201
2M ago
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
PremiumPress Releases
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
2M ago
JPMorgan Chase Ends Major Stake in Alterity Therapeutics
PremiumCompany Announcements
JPMorgan Chase Ends Major Stake in Alterity Therapeutics
2M ago
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
PremiumPress ReleasesAlterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
3M ago
Alterity Therapeutics Aims for ASX Listing Boost
PremiumCompany Announcements
Alterity Therapeutics Aims for ASX Listing Boost
3M ago
Alterity Therapeutics’ Breakthrough in Rare Disease Treatment
PremiumCompany Announcements
Alterity Therapeutics’ Breakthrough in Rare Disease Treatment
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100